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Screening for Multiple Endocrine Neoplasia Type 2A with 
DNA-Polymorphism Analysis 
Estelle M.-F. Lamothe,* Steven A. Narod,* Shari Miller,* Paul J. Goodfellow,^  David E. C. 
Cole,* Dawna Gilchrist,§ Zdenka Pausova,* David Goltzman,* and Geoffrey N. Hendy* 
Nine chromosome 10 DNA markers (FNRB. DI0S34, DlOZl, MEN203, DI0S94. RBP3, DI0S15, 
MBP 148.1 If DI0S22) were typed in tn'o large Canadian pedigrees with multiple endocrine 
neoplasia type 2A (MEN 2A). These markers and the gene for MEN 2A (MEN2A) are believed to he in 
one linkage group spanning approximately 15 cM (male). MEN203 andDlOS94 were informative and 
tightly linked to MEN2A with no recombinants observed in 26 meiotic events. DlOSl5 (MCK2). 
widely used in DNA genotyping predictions, demonstrated two recombinants in these tn'o families. 
The use of multiple flanking markers increases both the likelihood of informativeness and the 
accuracy of risk assessments for predictive testing. We were able to assign a risk estimate for all 10 
at-risk individuals. (Henry Ford Hosp MedJ 1992;40:224-6) 
Multiple endocrine neoplasia type 2A (MEN 2A) is the as-sociation of three tumors: medullary thyroid carcinoma 
(MTC), pheochromocytoma, and parathyroid tumors. Eariy rec-
ognition and removal of occuh MTCs significantly reduces the 
risk of subsequent metastases, and the screening of at-risk rela-
tives of affected individuals for early neoplastic changes is en-
couraged. MEN 2A is a dominantiy inherited genetic disorder 
which has been mapped to chromosome 10 [see (1) and refer-
ences therein]. Screening can be selectively targeted to individ-
uals at high risk of developing cancer through the use of closely 
linked DNA markers (2,3). In countries where systematic 
screening programs for MEN 2A have been instituted (France, 
Germany, Great Britain, the Netherlands, Sweden), 25% of 
MTC cases have been found to be familial. 
We present a DNA analysis for screening two such families. 
These pedigrees contain members located in various provinces 
of Canada. Nationwide collaborations which asseinble various 
branches of MEN 2A fainilies can help in the early detection of 
individuals at high risk for MTC. 
Methods 
Strategy for linkage analysis 
The MEN 2A gene (MEN2A) was first assigned to chromo-
some 10 tightly linked to the interstitial retinol binding protein 
(RBP3) locus (0 = 0.02) and to the anonymous MCK2 sequence 
(9 = 0.05) at lOql 1.2 (4,5). More distal markers on the long arm 
of chromosome 10 include the mannose binding protein cDNA 
probe 48.11 (0 = 0.6) and the anonymous probe TB10.16 (0 = 
0.10). Two fianking markers have been identified on I Op: the 
gene for the beta subunit of the fibronectin receptor (FNRB) (0 
= 0.06) and the anonymous sequence TB 14.34 (0 = 0.07). Re-
cently, a number of centromeric markers have been found to be 
informative and show no recombination with the MEN 2A lo-
cus. These include the centromeric alphoid sequence DlOZl; 
MEN203 and D10S94 (Fig 1). 
By using a combination of fianking and centromeric restric-
tion fragment length polymorphisms (RFLPs), almost all indi-
viduals will be heterozygous and all families potentially infor-
mative. If carrier probabilities approaching 0% or 100% can be 
obtained in at-risk individuals, those identified at high risk can 
be targeted for selective screening for eariy symptoms. We have 
used nine chromosome 10 markers to analyze the two Canadian 
families [Table 1,(6-15)]. 
DNA analysis 
DNA was extracted from peripheral blood lymphocytes with 
a modified phenolchloroform method. Five |Xg aliquots of DNA 
were digested with each of six enzymes: Banll, PvuII, Hinfi, 
Bglll , TaqI, and Mspl. The DNA fragments were separated by 
electrophoresis on 0.8% agarose gels with TPE buffer. The 
DNA was denatured and blotted onto charged nylon membranes 
(Nytran) by the passive Southern method and baked at 80 °C for 
1 to 2 hours before being hybridized with [-^ -P]-dCTP radiola-
beled probes. Blots were washed under high stringency condi-
tions and exposed to Kodak X-AR Omat film with two High 
Plus intensifying screens at -85 °C for one to seven days. The 
blots were then subjected to high temperature/low salt stripping 
and rehybridized repeatedly. See Table 2 for the order of probes 
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Fig I—Chromosome 10: A genetic map of nine markers flank-
ing the MEN 2A locus. Recombination fractions from the cen-
tromere (DlOZl) (combined male and female) are shown above 
each marker as a percentage. 
used. Blots probed with TB 14.34 and MEN203 were hybridized 
in the presence of 100 jig/mL of sheared human placental DNA. 
LOD scores were calculated with the LINKAGE program (16) 
using a gene frequency of 1:50,000 and published penetrance 
figures (2). 
Results and Discussion 
Individuals in these extended families are highly motivated, 
and participation of both affected and unaffected members has 
been good. The two families consist of 26 sampled individuals, 
including 12 affected individuals. Eight had MTC only and four 
had both MTC and pheochromocytomas. 
Family 1 (Fig 2) was referred to us for DNA analysis for three 
individuals in generation IV with a 50% a priori risk (at birth) of 
inheriting the MEN 2A allele from their mother II-4. Markers 
FNRB, D10S34, MEN203, D10S94, RBP3, D10S15, and 
D10S22 are all informative. Segregation of the.se is such that all 
at-risk individuals have been assigned considerably lowered 
risk of inheriting the mutant allele (Table 3). Individuals III-2, 
III-4, and III-6 are assessed at < 1%, given both flanking and 
centromeric informative meioses. There has apparentiy been a 
recombination between markers FNRB and MEN203 in indi-
vidual III-2, but the MEN 2A gene is more likely to have segre-
gated with the closely linked centromeric marker MEN203. 
Family 2 is somewhat more complex. Fig 3 shows the hap-
lotypes most likely segregating in this famOy. Flanking markers 
FNRB and D10S15 are informative. MEN2A segregates with 
the haplotype B21A1121 in the second generation. Therefore, 
individuals ITS, in-6, ni-7, III-8, IIMO, I V - l , and IV-2 all have 
a lowered risk for inheriting the MEN 2A allele. Individuals III-
1 and III-4 each show a recombination between FNRB and 
DlOSl5. MEN2A segregates with DlOSl5 in I f l - l and with 
FNRB in III-4. Individual III-I's children are at low risk of hav-
ing inherited the mutant MEN 2A allele since III - l is informa-
tive with the centromeric probe D10S94 and with D1 OS 15. 
Ten unaffected individuals at 50% risk at birth were offered 
risk assessment (Table 3). For all of these, DNA analysis re-
sulted in risk assessments sufficiently low which appear to jus-
tify their removal from the screening program. Baseline pen-
tagastrin tests have all been normal. There were no equivocal re-
sults. 
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Fig 2—Family I pedigree and haplotype analysis with chromo-
some 10 RFLP loci. FNRB, D10S94, and IRBP.H4 alleles repre-
sent individual marker haplotypes using multiple RFLPs for 
each probe. The boxed haplotype is that segregating with the 
MEN 2A gene. The arrows indicate the positions of recombina-
tions in affected individuals. 
Table 1 
Chromosome 10 Pericentric DNA Markers 
Res. 
I.OCUS Probe Location Enzyme PIC 
FNRB (6) pGEM32 lOpIl.2 Banll 
Hinf 
0.71 
D10S34 (7) TB 14.34 TaqI 
DlOZl (8) pIORPS lOCEN-qll.2 Hinn 0.50 
MEN2()3 (9) 10 CEN Bgll l 
D10S94(10.11) EC03.')0 10 CEN Mspl 
TaqI 
c23 10 CEN PvuII 
RBP3 (4,12) IRBP-H4 IOqlI.2 Bglll 
Mspl 
0.67 
D10SLS(13) MCK2 lOqlI.2 Mspl 0.35 
MBP (14) 48.11 lOql 1.2-21 TaqI 
D10S22(Li) TB10.I63 10q21.1 Mspl 
PIC = polymorphic information content. 
Table 2 
Strategy for DNA Screening Analysis 
Rest. Enzyme Probes 
Banll c23 
PvuII FNRB 
Hinfl DIOZI FNRB 
Bglll 1RBP-H4 MEN203 FNRB 
TaqI 48.11 EC0350 TB 14.34 
M.spl MCK2 IRBP-H4 ECO350 TBIO. 163 
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Fig 3—Family 2 pedigree and haplotype analysis with chromo-
some 10 RFLP loci. The boxed haplotype is that segregating 
with the MEN 2A gene. Recombinations are evident in individu-
als lll-l and III-4. The.se occurred in II I within the ho.xed areas 
hounded by the dashed lines. 
The use of both fianking and centromeric RFLPs in MEN 2A 
families ensures that preclinical diagnoses are as accurate as 
possible. The strategy employed here provides a comprehensive 
analysis using as little as 30 ^g of DNA. As more centromeric 
markers are identified, and as the mapping of MEN 2A im-
proves, the accuracy of diagnosis will improve. 
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